Endo Pharmaceuticals returns Urocidin global rights to Bioniche Bioniche Life Sciences announced that global rights to Urocidin are being returned to the company from Endo Pharmaceuticals, a subsidiary of Endo Health Solutions (ENDP). On November 5, it was announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer being run by Endo was being discontinued. The trial was not recruiting at the expected rate and, after discussions with the U.S. FDA regarding the clinical trial design, Endo decided to end the trial before its scheduled completion. As a result of this decision, the two companies came to an agreement that a mutually favorable path forward for the product is to return global rights to Bioniche. In exchange for this agreement, Endo will receive a royalty on future revenue.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.